ProCE Banner Activity

Latest Insights on Ki-67 Use in HR-Positive/HER2-Negative Early Breast Cancer

Clinical Thought
Laura M. Spring, MD, a breast cancer medical oncologist, and Sunil Badve, MD, FRCPath, a surgical pathologist, provide insights into the role and utility of Ki-67 testing in HR-positive/HER2-negative early breast cancer in this expert commentary.

Released: September 26, 2022

Expiration: September 25, 2023

Share

Provided by

Provided by a partnership between the American Society for Clinical Pathology and Clinical Care Options, LLC.
ProCE Banner

Supporters

This activity is supported by an educational grant from

Lilly